Just a moment, the page is loading...
Discovery Fast Track
Challenge
NOTICE: The 2018 Australian Challenge is no longer accepting applications.
You can check the status of your application by clicking the "My proposals" and logging into your account.

2018 Discovery Fast Track Australian Challenge Process

Investigator submits a brief non-confidential proposal

  • Applications will be accepted starting March 19, 2018, and must be submitted no later than April 27, 2018.
  • The preliminary application will consist of a non-confidential, one-page summary including the therapeutic hypothesis, a brief description of the target, the level of completeness of the development of the target/screening assay.
  • Applicants will be asked to agree to a waiver stating that nothing they are supplying in the initial application is confidential and that she or he is entitled to make the disclosure to GSK.
  • All investigators who apply to the Challenge will be required to acknowledge that they have notified their Technology Transfer Office (TTO) that they intend to enter the Challenge. Specifically, investigators will be required to provide the email address for one of their institution's TTO staff members within the application itself.

Please click here to see an example of the submission form. (For information only. All applications must be submitted electronically via the portal).

GSK judges select the finalists

  • All applications will be reviewed by an expert panel of judges and rated based on pre-defined criteria. Their collective reviews will be used to determine the finalists.
  • Finalists will be selected and informed by mid-June, 2018. Feedback will be provided to non-successful applicants after this time.

Finalists submit proposal to GSK

  • Finalists and their institutions will be requested to sign a CDA to enable submission of an expanded description of the therapeutic hypothesis, supporting biology, target description and screen (3-5 pages) with a key emphasised therapeutic hypothesis which may include confidential data.
  • Finalists and their institutions will also be asked to provide:
    • A statement about whether the technology and materials are subject to contractual obligations and confirmation that the institution has the right to transfer such technology and materials to GSK.
    • Specific information required to complete due diligence is needed to ensure that the research and associated technology of the assay is unencumbered by any institutional or external obligations and that the proposed work is potentially amenable to high throughput screening.
    • A presentation outlining the proposal which they will present at a face-to-face with the judging panel.
  • Finalists will be assigned a GSK mentor who will provide advice and guidance to prepare for the final stage of the Challenge.
  • Finalists will be asked to initiate discussions with their TTO at their institution to confirm ability to execute the Challenge Materials Transfer Agreement (MTA) if the investigator is selected as a winner.

Finalists present their proposals to a panel of GSK experts

  • All finalists will present their proposals at a face-to-face meeting that will be reviewed by a panel of GSK drug discovery experts. All finalists will receive feedback about their concept from judging panel members. After all the proposals have been reviewed, the panel will select the winners. The panel's decision is final and GSK is unable to enter into correspondence regarding the decisions, but will provide detailed feedback to all finalists.
  • These meetings will be held in Melbourne, Australia during the week of August 13, 2018.

Winners selected and MTA signed

  • Provisional winners will be informed shortly after the face-to-meeting in August 2018. However, winner confirmation is conditional upon the execution of the challenge MTA by the winner's institution. We expect to publicly announce winners by the end of 2018.

Planning for the screening collaboration begins

  • Once winners are confirmed, a project team will be formed for each winner consisting of the winning investigator and our relevant GSK experts. The team will then begin to work together to design the screening cascade around their proposed approach.

© 2001-2018 GlaxoSmithKline plc. All rights reserved. Registered in England and Wales No. 3888792.
Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.